DB
ELAB icon

Danske Bank’s Elevai Labs ELAB Stock Holding History

Danske Bank’s Portfolio ELAB Stock Details ELAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Buy
+1
New +$3 ﹤0.01% 1138

Other funds holding ELAB

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Danske Bank's ELAB Position: Q2 2026 in Review

Danske Bank opened a new position in Elevai Labs (ELAB) in Q2 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #1138 among its holdings.

9 funds tracked by Wall St. Rank hold ELAB as of Q2 2026.

  • Danske Bank held 1 share of Elevai Labs worth $1 as of Q2 2026.
  • Elevai Labs was a new Danske Bank position in Q2 2026.
  • Elevai Labs made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1138 holding.
  • 9 funds tracked by Wall St. Rank held Elevai Labs as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.